Viridian Therapeutics Inc
Change company Symbol lookup
Select an option...
VRDN Viridian Therapeutics Inc
FBSI First Bancshares Inc (Missouri)
KGDEY Kingdee International Software Group Co Ltd
CMRA Comera Life Sciences Holdings Inc
ADI Analog Devices Inc
KEY KeyCorp
FNF Fidelity National Financial Inc
CTAQU Carney Technology Acquisition Corp. II
MUE BlackRock MuniHoldings Quality Fund II, Inc.
NC NACCO Industries Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company is engaged in developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.

Day's Change
-0.31 (-1.49%)
B/A Size
Day's High
Day's Low

Today's volume of 101,521 shares is on pace to be much lighter than VRDN's 10-day average volume of 389,877 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    2:20p ET 10/05/22
  • Last (size)
  • 52-Wk Range
    9.47 - 26.22
  • (05/09/22 - 08/17/22)
  • 79.1%
  • Market Cap
  • Shares Outstanding
  • -4.60
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.9
  • 72.12
  • (% of float 09/15/22)

Latest News

September 02, 2022
8:00 am ET
Globe Newswire
August 25, 2022
4:03 pm ET
Globe Newswire
August 17, 2022
6:00 am ET
Globe Newswire
August 16, 2022
9:35 am ET
August 15, 2022
4:01 pm ET
Globe Newswire
7:02 am ET
Globe Newswire
6:59 am ET
Globe Newswire
August 08, 2022
8:00 am ET
Globe Newswire
August 05, 2022
8:03 am ET
Globe Newswire
July 08, 2022
8:00 am ET
Globe Newswire
June 23, 2022
7:26 am ET
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.